2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction
2015
Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani GF, Lansky AJ, Ormiston J. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. EuroIntervention 2015, 10: 1383-90. PMID: 24801119, DOI: 10.4244/eijy14m05_03.Peer-Reviewed Original ResearchConceptsZotarolimus-eluting stentsLate lumen lossStent late lumen lossOptical coherence tomographyII trialMajor adverse cardiac eventsMean late lumen lossClinical safety endpointPrimary efficacy hypothesisAdverse cardiac eventsPrimary efficacy endpointStent thrombosis ratesMean neointimal thicknessSirolimus-eluting stentsQuantitative coronary angiographyZES patientsEfficacy endpointPrimary endpointSafety endpointVolume obstructionCardiac eventsCoronary angiographyThrombosis rateZES groupStrut coverage
2011
Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials
BEZENEK S, HERMILLER J, LANSKY A, YAQUB M, HATTORI K, CAO S, SOOD P, SUDHIR K. Low Stent Thrombosis Risk with the XIENCE V® Everolimus‐Eluting Coronary Stent: Evidence from Randomized and Single‐Arm Clinical Trials. Journal Of Interventional Cardiology 2011, 24: 326-341. PMID: 21443551, DOI: 10.1111/j.1540-8183.2011.00628.x.Peer-Reviewed Original ResearchConceptsEverolimus-Eluting Coronary Stent SystemDual antiplatelet therapyXIENCE VST ratesRisk factorsLow stent thrombosis ratesSingle-arm clinical trialOccurrence of STStent thrombosis riskAcademic Research ConsortiumStent thrombosis ratesPotential risk factorsCoronary stent systemLow ST ratesHigh compliance rateSPIRIT FIRSTAntiplatelet therapyThrombosis rateSPIRIT trialComplex patientsThrombosis riskClinical trialsStent systemThin strut designDrug usage
2010
EVALUATION OF THIENOPYRIDINE COMPLIANCE AND STENT THROMBOSIS RATES AFTER EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENT IMPLANTATION: 3-YEAR RESULTS FROM THE SPIRIT III ANALYSIS
Cox D, Sudhir K, Hermiller J, Applegate R, Gordon P, Doostzadeh J, Jonnavithula L, Koo K, Maloney T, Lansky A, Simonton C, Stone G. EVALUATION OF THIENOPYRIDINE COMPLIANCE AND STENT THROMBOSIS RATES AFTER EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENT IMPLANTATION: 3-YEAR RESULTS FROM THE SPIRIT III ANALYSIS. Journal Of The American College Of Cardiology 2010, 55: a191.e1791. DOI: 10.1016/s0735-1097(10)61792-5.Peer-Reviewed Original ResearchPaclitaxel-Eluting Stent ImplantationStent thrombosis ratesEverolimus-ElutingThrombosis rateStent implantation
2009
Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:
Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:. Catheterization And Cardiovascular Interventions 2009, 74: 719-727. PMID: 19530147, DOI: 10.1002/ccd.22067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCardiovascular DiseasesCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeWomen's HealthConceptsSPIRIT III trialIII trialsXIENCE VTaxus stentXience V stentTVF rateTAXUS paclitaxel-eluting stentRate of MACECoronary artery lesionsStent thrombosis ratesPercutaneous coronary interventionStent late lossPaclitaxel-eluting stentsCoronary stent systemHigher MACEMore hypertensionAngiographic characteristicsArtery lesionsCoronary interventionThrombosis rateAngiographic resultsClinical outcomesClinical benefitStent placementSubset analysis
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2004
High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularizationOne-year results from the SCORE randomized trial
GRUBE E, LANSKY A, HAUPTMANN K, DIMARIO C, DISCIASCIO G, COLOMBO A, SILBER S, STUMPF J, REIFART N, FAJADET J. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularizationOne-year results from the SCORE randomized trial. Journal Of The American College Of Cardiology 2004, 44: 1368-1372. DOI: 10.1016/s0735-1097(04)01351-8.Peer-Reviewed Original ResearchConceptsRestenosis rateStent thrombosisMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsTarget vessel revascularization rateEnd pointNon-Q-wave MIAngiographic restenosis rateCardiac event rateNovo coronary lesionsPrimary end pointUnacceptable safety profileVessel revascularization rateMyocardial infarction rateOpen-label trialStent thrombosis ratesClinical end pointsOne-year resultsQuantitative coronary angiographyCoronary revascularizationRevascularization ratesInfarction rateCardiac deathCoronary angiographyHigh-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization One-year results from the SCORE randomized trial
Grube E, Lansky A, Hauptmann K, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell M. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization One-year results from the SCORE randomized trial. Journal Of The American College Of Cardiology 2004, 44: 1368-1372. PMID: 15464315, DOI: 10.1016/j.jacc.2004.06.054.Peer-Reviewed Original ResearchConceptsRestenosis rateStent thrombosisMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsTarget vessel revascularization rateEnd pointNon-Q-wave MIAngiographic restenosis rateCardiac event rateNovo coronary lesionsPrimary end pointUnacceptable safety profileVessel revascularization rateMyocardial infarction rateOpen-label trialStent thrombosis ratesClinical end pointsOne-year resultsQuantitative coronary angiographyCoronary revascularizationRevascularization ratesInfarction rateCardiac deathCoronary angiography
2000
Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses
Lansky A, Roubin G, O’Shaughnessy C, Moore P, Dean L, Raizner A, Safian R, Zidar J, Kerr J, Popma J, Mehran R, Kuntz R, Leon M. Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses. Circulation 2000, 102: 1364-1368. PMID: 10993853, DOI: 10.1161/01.cir.102.12.1364.Peer-Reviewed Original ResearchConceptsCoronary stenosisPalmaz-SchatzElective treatmentDe novo native coronary stenosisStent minimal lumen diameterMultivariate logistic regression analysisPrimary end pointTarget lesion revascularizationFree survival rateStent thrombosis ratesLong-term followNative coronary stenosisMinimal lumen diameterLogistic regression analysisPalmaz-Schatz stentsBalloon angioplasty proceduresRestenosis frequencyAngiographic restenosisLesion revascularizationProspective multicenterTLR rateFree survivalAcute treatmentConsecutive patientsDiabetes mellitus